Why Gilead Sciences (GILD) Appeals to Income Investors in the Pharma Sector
The company rose to prominence during the COVID-19 pandemic thanks to its antiviral drug remdesivir, one of the earliest approved treatments for the virus.
Gilead Sciences Inc. (GILD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | HealthInvest Partners AB Anders Hallberg And Carl Bennet | 73,165 | $8,111,804 | -5% | 3.47% |
| 2. | Ayrshire Capital Management John Nevin Jr. | 5,400 | $598,698 | 0.29% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $99.92 | 10,000 | $999,150.00 | 88,173 | 2015-02-06 | Filing | |
| $43.05 | 10,000 | $430,493.00 | 69,458 | 2013-02-28 | Filing | |
| $44.00 | 10,000 | $439,955.00 | 26,097 | 2012-02-22 | Filing | |
| $38.60 | 8,704 | $335,974.40 | 12,800 | 2010-05-04 | Filing | |
| $38.59 | 4,096 | $158,064.64 | 4,096 | 2010-05-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $111.03 | 3,000 | $333,090.00 | 117,168 | 2025-07-15 | Filing | |
| $111.03 | 2,500 | $277,575.00 | 162,610 | 2025-07-15 | Filing | |
| $109.74 | 5,000 | $548,700.00 | 8,920 | 2025-07-14 | Filing | |
| $111.15 | 600 | $66,688.02 | 615,725 | 2025-06-30 | Filing | |
| $110.40 | 9,400 | $1,037,795.72 | 616,325 | 2025-06-30 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,742,656 | $414,948,273 | 0.67% | |
| 2. | 2,403,630 | $266,490,459 | 0.3% | |
| 3. | 1,319,796 | $146,325,783 | 0.22% | |
| 4. | 969,807 | $107,522,447 | 1.52% | |
| 5. | 663,697 | $73,584,133 | 2.33% |
News See All
14 Best Pharma Dividend Stocks to Buy in 2025
The US pharmaceutical industry has undergone notable shifts in recent years, influenced by factors such as the COVID-19 pandemic, expanded collaborations across the value chain, and ongoing changes in...
Bernstein Maintains Buy Rating on Gilead Sciences (GILD) Stock
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In.
Gilead Sciences (GILD) Reaches Deal to Offer HIV Vaccine to Low and Middle-Income Nations
Gilead Sciences, Inc. (NASDAQ:GILD) is one of Goldman Sachs’ top healthcare stock picks.
Goldman Sachs Healthcare Stocks: Top 10 Stock Picks
The healthcare sector has been under pressure, underperforming the S&P 500 over the past several years.
10 Best Large Cap Value Stocks to Invest In
According to Goldman Sachs Research, US stocks may rally more than previous forecast, as the US Fed is expected to cut rates earlier than anticipated.
Gilead Sciences, Inc. (GILD): A Bull Case Theory
We came across a bullish thesis on Gilead Sciences, Inc. on Dividend Talks’s Substack. In this article, we will summarize the bulls’ thesis on GILD.
Gilead Sciences, Inc. (GILD) Reports Advances in HIV Treatment with Phase 2/3 Clinical Trial Update
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio.
Gilead Sciences (GILD) Announces that US FDA Approves Yeztugo®as pre-exposure prophylaxis (PrEP)
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires.
10 Best Value Stocks to Buy According to Billionaires
The H1 2025 has been a roller coaster ride for the investors. During the initial months of the year, the benchmarks touched record highs, according to Bank of America Private Bank.
Billionaire Hedge Funds
